{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:33:43Z","timestamp":1786995223610,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12EY27720"],"award-info":[{"award-number":["K12EY27720"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NOI-EY-0-2127"],"award-info":[{"award-number":["NOI-EY-0-2127"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY10572"],"award-info":[{"award-number":["P30EY10572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ophtha.2019.11.016","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T02:14:26Z","timestamp":1574734466000},"page":"784-792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"127","author":[{"given":"Panos G.","family":"Christakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Agr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7312-9719","authenticated-orcid":false,"given":"Michael L.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci E.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Peter","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-9802","authenticated-orcid":false,"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2253-1772","authenticated-orcid":false,"given":"Tiarnan D.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ophtha.2019.11.016_bib1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/eye.2015.288","article-title":"Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013","volume":"30","author":"Quartilho","year":"2016","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.ophtha.2019.11.016_bib2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2019.11.016_bib3","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.ophtha.2019.11.016_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.ophtha.2019.11.016_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ophtha.2019.11.016_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005139.pub2","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration","author":"Vedula","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.ophtha.2019.11.016_bib7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2008.08.012","article-title":"Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"115","author":"Ip","year":"2008","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ophtha.2019.11.016_bib8","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"Solomon","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ophtha.2019.11.016_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2019.11.016_bib10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","article-title":"Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study","volume":"159","author":"Bhisitkul","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"9900","key":"10.1016\/j.ophtha.2019.11.016_bib11","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ophtha.2019.11.016_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","article-title":"Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial","volume":"126","author":"Bailey","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2019.11.016_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2019.11.016_bib14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","article-title":"Macular atrophy in the HARBOR study for neovascular age-related macular degeneration","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2019.11.016_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0197-2456(99)00031-8","article-title":"The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1","volume":"20","year":"1999","journal-title":"Control Clin Trials"},{"issue":"5","key":"10.1016\/j.ophtha.2019.11.016_bib16","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0002-9394(01)01218-1","article-title":"The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study report number 6","volume":"132","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2019.11.016_bib17","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/archopht.1991.01080090044025","article-title":"Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2019.11.016_bib18","first-page":"198","volume":"119","author":"Bressler","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2019.11.016_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2019.11.016_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A\u00a0large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.ophtha.2019.11.016_bib21","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.ophtha.2018.05.028","article-title":"Progression of geographic atrophy in age-related macular degeneration: AREDS2 report number 16","volume":"125","author":"Keenan","year":"2018","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ophtha.2019.11.016_bib22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3928\/23258160-20151008-02","article-title":"Optical coherence tomography angiography reveals mature, tangled vascular networks in eyes with neovascular age-related macular degeneration showing resistance to geographic atrophy","volume":"46","author":"Dansingani","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2019.11.016_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajo.2017.07.009","article-title":"Treatment-naive quiescent choroidal neovascularization in geographic atrophy secondary to nonexudative age-related macular degeneration","volume":"182","author":"Capuano","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2019.11.016_bib24","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642019322973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642019322973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:08:17Z","timestamp":1758982097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642019322973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0161642019322973"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.016","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}